Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.
2.
3.

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP Jr, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.

Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011.

PMID:
19014833
4.

The efficacy and safety of solifenacin in patients with overactive bladder syndrome.

Oresković S, But I, Banović M, Goldstajn MS.

Coll Antropol. 2012 Mar;36(1):243-8.

PMID:
22816227
5.

Solifenacin significantly improves all symptoms of overactive bladder syndrome.

Chapple CR, Cardozo L, Steers WD, Govier FE.

Int J Clin Pract. 2006 Aug;60(8):959-66. Review. Erratum in: Int J Clin Pract. 2006 Nov;60(11):1517-8.

6.

Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.

Wagg A, Wyndaele JJ, Sieber P.

Am J Geriatr Pharmacother. 2006 Mar;4(1):14-24.

PMID:
16730617
7.

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.

Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A; YM-905 Study Group.

BJU Int. 2004 Feb;93(3):303-10.

PMID:
14764127
8.

Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.

Garely AD, Lucente V, Vapnek J, Smith N.

Ann Pharmacother. 2007 Mar;41(3):391-8. Epub 2007 Mar 6.

PMID:
17341526
9.

Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.

Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, Schulz J, Radomski S, Drutz H, Barkin J, Paradiso-Hardy F.

J Urol. 2010 May;183(5):1892-8. doi: 10.1016/j.juro.2010.01.012. Epub 2010 Mar 29.

PMID:
20303119
10.

Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study.

Mattiasson A, Masala A, Morton R, Bolodeoku J; SOLAR Study Group.

BJU Int. 2010 Apr;105(8):1126-35. doi: 10.1111/j.1464-410X.2009.08910.x. Epub 2009 Oct 10.

11.

Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).

Cardozo L, Amarenco G, Pushkar D, Mikulas J, Drogendijk T, Wright M, Compion G; SUNRISE Study Group.

BJU Int. 2013 May;111(5):804-10. doi: 10.1111/j.1464-410X.2012.11654.x. Epub 2013 Jan 7.

12.

Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.

Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M; Japanese Solifenacin Study Group.

BJU Int. 2007 Sep;100(3):579-87.

13.

Pharmacologic management of overactive bladder.

Lam S, Hilas O.

Clin Interv Aging. 2007;2(3):337-45. Review.

14.

Solifenacin succinate for the treatment of overactive bladder.

Hoffstetter S, Leong FC.

Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):345-50. doi: 10.1517/17425250902762866 . Review.

PMID:
19331596
15.

Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.

Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, Kim JC, Seo JT, Paick JS, Kim HJ, Na YG, Lee JG.

Int J Clin Pract. 2008 Nov;62(11):1675-83. doi: 10.1111/j.1742-1241.2008.01898.x.

16.

Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial.

Vardy MD, Mitcheson HD, Samuels TA, Wegenke JD, Forero-Schwanhaeuser S, Marshall TS, He W.

Int J Clin Pract. 2009 Dec;63(12):1702-14. doi: 10.1111/j.1742-1241.2009.02209.x.

PMID:
19930331
17.
18.

Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.

Capo' JP Jr, Laramée C, Lucente V, Fakhoury A, Forero-Schwanhaeuser S.

Int J Clin Pract. 2008 Jan;62(1):39-46. Epub 2007 Nov 23.

PMID:
18036164
19.

Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.

Haab F, Corcos J, Siami P, Glavind K, Dwyer P, Steel M, Kawakami F, Lheritier K, Steers WD.

BJU Int. 2006 Nov;98(5):1025-32. Epub 2006 Jul 28.

20.

[Solifenacin in the treatment of overactive bladder: results of a randomized double-blind, placebo-controlled study].

Ibinaeva IS, Apolikhina IA, Makhmedzhanova FN, Muslimova SZ.

Urologiia. 2012 Sep-Oct;(5):24-8. Russian.

PMID:
23342612

Supplemental Content

Support Center